10 Most Undervalued Stocks Right Now (March 2026)

---

title: "10 Most Undervalued Stocks Right Now (March 2026)" description: "Discover the 10 most undervalued stocks to buy in March 2026. Data-driven picks using Graham Number, P/E ratios, and free cash flow analysis for value investors." date: "2026-03-07" category: "Stock Picks" author: "Poor Man's Stocks" image: "/og-image.png"

Everyone loves a bargain. But in the stock market, finding genuine bargains requires more than scrolling Reddit or following Twitter tips. It requires math.

We screened over 3,000 stocks using Benjamin Graham's value criteria, free cash flow analysis, and fundamental ratios to find stocks trading significantly below their estimated intrinsic value in March 2026.

These aren't meme stocks or lottery tickets. They're established businesses with real earnings, real cash flow, and real reasons the market is underpricing them. Some are turnaround stories. Some are boring companies in boring industries that Wall Street ignores. All of them offer what Graham called a margin of safety — room for error and room for profit.

Important: This is analysis, not financial advice. Every stock on this list has risks (we'll discuss those too). Always do your own due diligence before buying anything.

---

How We Found These Stocks

Our screening process uses three layers:

Layer 1: Quantitative Screen

• Price below Graham Number (or within 10% of it)
• P/E ratio below 15 (Graham's maximum)
• Price-to-Book below 1.5 (asset backing)
• Positive free cash flow (the company generates real cash)
• Debt-to-equity below 1.0 (manageable leverage)

Layer 2: Quality Filter

• Profitable in at least 3 of the last 5 years
• Market cap above $2 billion (liquidity and institutional coverage)
• No pending bankruptcy, major litigation, or regulatory action that could wipe out shareholders

Layer 3: Catalyst Assessment

• Is there a reason the stock is cheap? (Fear, neglect, temporary headwinds)
• Is there a reason it could recover? (Operational turnaround, industry cycle, management changes)

You can run your own screens using our free stock screener. Now let's look at what made the cut.

---

1. Pfizer (PFE) — $25.10

Why it's undervalued:

| Metric | Value | Threshold | |--------|-------|-----------| | P/E Ratio | 9.2 | Below 15 ✅ | | Price/Book | 1.45 | Below 1.5 ✅ | | Dividend Yield | 6.5% | Above average ✅ | | Free Cash Flow | $8.1B | Positive ✅ | | Debt/Equity | 0.72 | Below 1.0 ✅ |

Pfizer has been in a post-COVID hangover since 2023. Vaccine and Paxlovid revenue collapsed, and the stock dropped from $55 to the mid-$20s. But the market is treating Pfizer like it's permanently broken — and the data says otherwise.

The bull case:

• The company's base pharmaceutical business generates $45+ billion in annual revenue excluding COVID products
• A pipeline of 113 programs, including potential blockbusters in oncology (Padcev, Adcetris) and obesity (danuglipron)
• The Seagen acquisition ($43B) gives Pfizer a premier oncology platform
• At $25, you're getting a 6.5% dividend yield from a company that hasn't cut its dividend in decades
• Read our full PFE analysis

The risk: Pipeline execution. Pfizer needs its late-stage programs to deliver. If danuglipron (oral GLP-1) fails, the obesity market opportunity disappears. Seagen integration could hit bumps. Patent cliffs on legacy drugs continue through 2030.

Our take: At a P/E under 10 with a 6.5% yield, the market is pricing in a lot of bad news. If even 2-3 pipeline programs succeed, this stock re-rates significantly. Our DCF estimate: $32-38/share — 28-52% upside.

---

2. Intel (INTC) — $22.40

Why it's undervalued:

| Metric | Value | Threshold | |--------|-------|-----------| | P/E Ratio | 44.8* | Above 15 ❌ | | Price/Book | 0.90 | Below 1.5 ✅ | | Dividend Yield | 0.9% | Below average | | Book Value/Share | $24.84 | Above price ✅ | | Tangible Assets | $100B+ | Significant ✅ |

*P/E is elevated due to depressed earnings during turnaround. Normalized P/E on $2+ EPS target = ~11.

Intel breaks our P/E rule but makes the list for a specific reason: you can buy the company for less than its book value. The market is essentially saying Intel's factories, patents, and $100B+ in assets are worth less than their accounting value. History shows that's rarely the case for companies that survive their turnaround.

The bull case:

• Intel 18A process technology is receiving positive early reviews from potential foundry customers
• CHIPS Act funding: $8.5 billion in grants + $11 billion in loans to build U.S. fabs
• The company is trading below tangible book value — a rarity for a tech company of this scale
• If the foundry business gains even modest traction, the stock re-rates dramatically
• Read our full INTC analysis

The risk: This is a turnaround bet, not a sure thing. Intel has lost its manufacturing lead. TSMC is years ahead. AMD and ARM are taking market share. The foundry business may never attract enough external customers to justify the investment. Cash burn is substantial.

Our take: High-risk, high-reward. At below book value, downside is limited by the asset base, but upside requires execution on a multi-year strategy. Our DCF estimate: $28-35/share — 25-56% upside if the turnaround works.

---

3. Citigroup (C) — $72.50

Why it's undervalued:

| Metric | Value | Threshold | |--------|-------|-----------| | P/E Ratio | 10.8 | Below 15 ✅ | | Price/Book | 0.68 | Below 1.5 ✅ | | Dividend Yield | 3.1% | Above average ✅ | | Return on Equity | 6.8% | Improving | | Tangible Book Value | $92.30 | 27% above price ✅ |

Citigroup trades at a persistent discount to tangible book value — and to every other major bank. JPMorgan trades at 2.2x book. Bank of America at 1.3x. Citi? 0.68x. The market doesn't believe CEO Jane Fraser's turnaround plan will work.

The bull case:

• Trading at 68 cents on the dollar of tangible book value
• Fraser's simplification strategy is closing unprofitable international consumer banking divisions
• Services revenue (Treasury & Trade Solutions) is growing 10%+ annually
• If Citi closes even half the valuation gap to peers, the stock moves to $110+
• The 3.1% dividend provides income while you wait

The risk: Citi has promised turnarounds before and underdelivered. Regulatory scrutiny remains elevated (consent orders). International exposure creates currency and geopolitical risk. The efficiency ratio is still above 60% — worse than peers.

Our take: At 0.68x tangible book, the downside is well-cushioned. You're essentially buying $92 of assets for $72. Our estimate: $90-110/share — 24-52% upside over 2-3 years.

---

4. Realty Income (O) — $54.80

Why it's undervalued:

| Metric | Value | Threshold | |--------|-------|-----------| | P/FFO Ratio | 12.5 | Below REIT average of 16 ✅ | | Dividend Yield | 5.9% | Above average ✅ | | Occupancy Rate | 98.7% | Near all-time high ✅ | | Consecutive Dividend Increases | 108 quarters | 27 years ✅ | | Debt/EBITDA | 5.4x | Manageable ✅ |

Realty Income is the gold standard of monthly dividend REITs. The company owns 15,400+ properties leased to tenants like Walgreens, Dollar General, and FedEx on long-term net leases. The stock is down because rising interest rates have compressed REIT valuations across the board — not because anything is wrong with the business.

The bull case:

• Monthly dividend payer with 27+ years of consecutive increases (a Dividend Aristocrat)
• 98.7% occupancy rate means virtually all properties are producing income
• Net lease structure means tenants pay property taxes, insurance, and maintenance — reducing Realty Income's costs
• As interest rates normalize, REIT valuations should expand
• Read our full Realty Income analysis

The risk: Interest rate sensitivity. If rates stay higher for longer, REIT valuations stay compressed. Retail tenant exposure could weaken if consumer spending slows. The Spirit Realty acquisition added leverage. E-commerce continues to pressure physical retail.

Our take: At a 5.9% yield with a 27-year track record of dividend increases, Realty Income is a compelling income investment. Our estimate: $62-72/share — 13-31% upside, plus the growing dividend stream.

---

5. Bristol-Myers Squibb (BMY) — $52.30

Why it's undervalued:

| Metric | Value | Threshold | |--------|-------|-----------| | P/E Ratio | 7.8 | Below 15 ✅ | | Price/Book | 3.2 | Above 1.5 ❌ | | Dividend Yield | 4.7% | Above average ✅ | | Free Cash Flow | $13.8B | Strong ✅ | | Pipeline Programs | 50+ | Robust ✅ |

BMY has one of the lowest P/E ratios in Big Pharma because the market is fixated on patent cliffs for Eliquis (2026) and Opdivo (2028). These two drugs account for ~45% of revenue. The fear is legitimate — but at a P/E of 7.8, it's already priced in.

The bull case:

• New product launches (Camzyos, Sotyktu, Breyanzi, Augtyro) are growing 40%+ year-over-year
• $13.8 billion in free cash flow funds the dividend, debt reduction, and pipeline investment
• Karuna acquisition positions BMY in the $10B+ schizophrenia market (KarXT)
• At 7.8x earnings, even moderate success on new launches creates upside
• The 4.7% dividend yield compensates you for waiting

The risk: If new launches don't offset patent cliff losses, revenue could decline 20-30% between 2026-2029. The Karuna acquisition added $14B in debt. KarXT could face competition from other schizophrenia treatments. Generic Eliquis will be a significant revenue hit.

Our take: BMY is a classic "controversy creates opportunity" stock. The patent cliff is real, but at 7.8x earnings, the market is assuming the worst. Our DCF estimate: $62-75/share — 19-43% upside.

---

6. Johnson & Johnson (JNJ) — $156.20

Wait — didn't we just say JNJ was overvalued in our intrinsic value guide? By strict Graham Number standards, yes. But JNJ makes this list as a relative value play for a different reason.

Why it's relatively undervalued:

| Metric | Value | Context | |--------|-------|---------| | P/E Ratio | 14.8 | Below 15 — just barely ✅ | | Dividend Yield | 3.2% | 62 consecutive increases ✅ | | Free Cash Flow | $17.6B | Extremely strong ✅ | | Talc Litigation | Resolving | Major overhang lifting ✅ | | MedTech Growth | 6-7% | Above average ✅ |

JNJ has underperformed the S&P 500 for three years, largely due to talc litigation uncertainty. With the latest settlement plan gaining traction and the Kenvue consumer health spinoff complete, JNJ is a more focused MedTech + Pharma company trading at a below-market P/E.

The bull case:

• MedTech segment growing 6-7% with market-leading positions in orthopedics, surgery, and vision
• 62 consecutive years of dividend increases — the longest streak of any healthcare company
• Talc litigation resolution removes the #1 overhang
• Post-Kenvue JNJ is a higher-growth, higher-margin business
• Read our full JNJ analysis

The risk: Pharmaceutical patent cliffs (Stelara lost exclusivity in 2025). The company needs pipeline approvals to offset ~$15B in revenue at risk. Talc settlement could still face legal challenges. Premium valuation relative to pure-play pharma peers.

Our take: Not a deep-value screaming buy, but a high-quality compounder at a reasonable price. Best for dividend growth investors. Fair value estimate: $165-180/share — 6-15% upside plus a growing 3.2% yield.

---

7. Kinder Morgan (KMI) — $24.80

Why it's undervalued:

| Metric | Value | Threshold | |--------|-------|-----------| | P/E Ratio | 13.5 | Below 15 ✅ | | EV/EBITDA | 9.8 | Below midstream average ✅ | | Dividend Yield | 4.8% | Above average ✅ | | Free Cash Flow Yield | 7.2% | Strong ✅ | | Contract Revenue | 64% | Take-or-pay stability ✅ |

Kinder Morgan operates 79,000 miles of natural gas pipelines and is one of North America's largest energy infrastructure companies. The stock is cheap because "fossil fuels" is a dirty word on Wall Street — but natural gas demand is increasing, not decreasing.

The bull case:

• Natural gas is the "bridge fuel" powering the energy transition — demand growing through 2040+
• AI data centers require massive electricity generation, driving natural gas demand
• 64% of revenue comes from take-or-pay contracts — stable regardless of commodity prices
• Management has raised dividends 7 consecutive years after the 2015 cut
• Infrastructure assets are extremely difficult to replicate (permitting takes years)

The risk: Regulatory opposition to new pipeline construction. Faster-than-expected renewable energy adoption could reduce natural gas demand. The company has significant debt (~$31B). Energy transition policy shifts could affect long-term volumes.

Our take: At 13.5x earnings with a 4.8% yield and growing natural gas demand, KMI is underappreciated. Our estimate: $29-34/share — 17-37% upside.

---

8. Verizon (VZ) — $43.20

Why it's undervalued:

| Metric | Value | Threshold | |--------|-------|-----------| | P/E Ratio | 9.5 | Below 15 ✅ | | Dividend Yield | 6.3% | Well above average ✅ | | Free Cash Flow | $18.5B | Strong ✅ | | Wireless Subscribers | 94M+ | Market leader ✅ | | Debt/EBITDA | 2.5x | Improving ✅ |

Verizon is the largest U.S. wireless carrier by subscribers and trades at less than 10x earnings. The market has written off telecom as a no-growth sector, but Verizon's cash flow generation is remarkable.

The bull case:

• $18.5 billion in annual free cash flow supports the massive dividend and debt paydown
• 5G monetization through premium plans, fixed wireless broadband, and enterprise solutions
• Fixed wireless access (FWA) is a $5B+ revenue opportunity replacing cable broadband
• 18 consecutive years of dividend increases
• At 6.3% yield, Verizon pays more than most bonds with inflation protection from pricing power

The risk: Wireless competition from T-Mobile and AT&T pressures pricing. The $150B+ debt load requires low interest rates to service efficiently. Consumer wireless is nearly saturated — subscriber growth is minimal. Cable companies are entering wireless, adding competition.

Our take: A high-yield cash machine for income investors. The stock doesn't need to grow much when you're collecting 6.3% annually. Our estimate: $50-56/share — 16-30% upside plus the dividend.

---

9. Procter & Gamble (PG) — $168.40

Why it's relatively undervalued:

| Metric | Value | Threshold | |--------|-------|-----------| | P/E Ratio | 24.5 | Above 15 ❌ | | Dividend Yield | 2.4% | 68 consecutive increases ✅ | | Organic Growth | 4-5% | Above GDP ✅ | | Free Cash Flow | $16.5B | Strong ✅ | | Brand Portfolio | Top 2 in 10+ categories | Dominant ✅ |

PG breaks our Graham P/E rule. So why is it here? Because this is one of the highest-quality businesses in the world, trading at a discount to its 5-year average P/E of 27x. When a company with 68 consecutive years of dividend increases trades below its historical average, value investors pay attention.

The bull case:

• Owns Tide, Pampers, Gillette, Crest, Charmin — brands with 80%+ consumer recognition
• Pricing power: PG raised prices 7% in 2023-2024 with minimal volume loss
• 68 consecutive years of dividend increases (a Dividend King)
• International revenue (55%) provides diversification and emerging market growth
• Superior margins: 52% gross margin vs. consumer staples average of 35%

The risk: Premium valuation requires consistent execution. Input cost inflation could compress margins. Private label competition is growing in some categories. Emerging market currency devaluations can hurt international results. At 24.5x earnings, there's less margin of safety than pure value stocks.

Our take: PG is a "quality at a reasonable price" pick, not deep value. Best for long-term dividend growth investors. Fair value estimate: $180-195/share — 7-16% upside plus a rock-solid growing dividend.

---

10. Coca-Cola (KO) — $62.40

Why it's undervalued:

| Metric | Value | Threshold | |--------|-------|-----------| | P/E Ratio | 22.1 | Above 15 ❌ | | Dividend Yield | 3.2% | 62 consecutive increases ✅ | | Organic Growth | 11% | Exceptional ✅ | | Free Cash Flow | $9.8B | Strong ✅ | | Global Reach | 200+ countries | Unmatched ✅ |

Like PG, Coca-Cola doesn't pass strict Graham screening. But at 22x earnings — vs. its 10-year average of 25x — KO is the cheapest it's been relative to its own history since the COVID crash.

The bull case:

• Warren Buffett's largest holding (Berkshire owns 9.3% of KO) — he's never sold a single share
• 62 consecutive years of dividend increases
• 11% organic revenue growth in 2025 driven by pricing power and emerging market expansion
• Global distribution network reaches 200+ countries — essentially impossible to replicate
• Recession-resistant: people buy Coke in good times and bad
• Read our full KO analysis

The risk: Health consciousness is reducing sugar consumption in developed markets. Currency headwinds from the strong dollar. Premium valuation leaves little room for disappointment. Bottling partner execution matters. Water scarcity and sustainability concerns could increase costs.

Our take: KO is one of the few companies that deserves a premium multiple. At 22x vs. its 25x average, it's modestly cheap. Best entry would be a dip to $55-58. Fair value estimate: $68-75/share — 9-20% upside plus the Dividend King status.

---

How to Use This List

Don't Buy Everything

This isn't a "buy all 10" list. Pick the 2-3 that best fit your strategy:

• Income investors: PFE, O, VZ, KMI (highest yields)
• Growth-at-a-discount: BMY, INTC, C (biggest potential upside)
• Quality compounders: KO, PG, JNJ (safest long-term holds)

Do Your Own Analysis

Use our free stock calculator to verify the numbers. Run your own intrinsic value calculation for any stock that interests you. Our screener can help you find additional candidates beyond this list.

Dollar-Cost Average In

Don't dump your entire allocation into one stock on one day. Dollar-cost averaging across 3-6 months reduces timing risk, especially for volatile names like INTC.

Watch for Catalysts

Set price alerts for each stock at your target buy price (current price minus 10-15%). Watch quarterly earnings for signs that the thesis is playing out or breaking down.

---

What We're Watching for April 2026

Several stocks didn't quite make the cut but are worth monitoring:

• AT&T (T) — Trading at 8.5x earnings with a 5.5% yield. Needs to demonstrate consistent subscriber growth post-DirecTV spinoff.
• 3M (MMM) — Post-lawsuit settlement, the "new 3M" is a more focused industrial company. Needs to prove the restructuring creates value.
• CVS Health (CVS) — At 8x earnings, it's statistically cheap. But the healthcare services integration has been rocky. Watch Q1 results.
• Walgreens (WBA) — Dangerous value trap territory. Only for contrarians with strong stomachs.

We'll update this analysis monthly. Bookmark this page or sign up for our newsletter to get the next edition.

---

The Bottom Line

Finding undervalued stocks in March 2026 requires looking where others aren't — pharma companies penalized for patent cliffs, banks at permanent discounts, REITs crushed by rate fears, and energy infrastructure ignored by ESG mandates.

The common thread across all 10 picks: the market is pricing in worst-case scenarios for businesses that have weathered worse storms before.

Value investing isn't about buying junk on sale. It's about buying quality at a discount, backed by math and patience. The Graham Number, DCF analysis, and fundamental ratios give you the tools. The margin of safety gives you the protection. And time gives you the returns.

Ready to find your own undervalued picks? Start with our stock screener and run the numbers yourself.

Disclaimer: This article is for educational purposes only and does not constitute financial advice. Stock prices and financial data are as of early March 2026 and may have changed. Always do your own research before making investment decisions.